Company intelligence / Profile preview

Xiamen Innovax Biotech Co., Ltd.

Xiamen, Fujian, Chinadcvmn.org ↗

Ownership: Private
Development stage: Commercial

Overview

Innovax has successfully developed and commercialized the world's first Hepatitis E Vaccine (Hecolin®) launched in China in 2012, and a Cervical Cancer Vaccine (Cecolin® - HPV16&18 bivalent) approved in 2019. Their 9-valent HPV vaccine is currently in Phase III clinical trials[1][7][8].

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: Recombinant vaccinesVirus-like particle vaccinesGenetically engineered subunit vaccinesConjugated vaccines
Industry: Biotech

Drug pipeline

23 assets

Cecolin 9

Approved

22 more assets in the full pipeline.

Request access →

Partnerships

GSK (formerly GlaxoSmithKline)Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Xiamen University

Beyond the preview

Go deeper on Xiamen Innovax Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiamen Innovax Biotech Co., Ltd..

Explore the full profile